Ratings by Oppenheimer (Leland Gershall)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/25/2026 | Capricor Therapeutics | CAPR | Upgrade | Outperform (Perform) |
6.80 (8.43) |
23.97% | Details | |
| 8/7/2026 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2026 | Capricor Therapeutics | CAPR | Downgrade | Perform (Outperform) |
6.57 (6.80) |
3.5% | Details | |
| 7/27/2026 | Capricor Therapeutics | CAPR | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/9/2026 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2026 | CalciMedica | CALC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2026 | Capricor Therapeutics | CAPR | Maintain | Outperform (Outperform) |
|
Details | ||
| 12/8/2025 | Capricor Therapeutics | CAPR | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2025 | CalciMedica | CALC | Maintain | Outperform (Outperform) |
|
Details | ||
| 11/14/2025 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2025 | Capricor Therapeutics | CAPR | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/23/2025 | Capricor Therapeutics | CAPR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/13/2025 | Capricor Therapeutics | CAPR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2025 | Capricor Therapeutics | CAPR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2025 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 12/4/2024 | Trevi Therapeutics | TRVI | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/14/2024 | Capricor Therapeutics | CAPR | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/8/2024 | Trevi Therapeutics | TRVI | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/7/2024 | Capricor Therapeutics | CAPR | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/23/2024 | Capricor Therapeutics | CAPR | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/17/2024 | Capricor Therapeutics | CAPR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/3/2024 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2024 | CalciMedica | CALC | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2024 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/10/2024 | CalciMedica | CALC | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2024 | CalciMedica | CALC | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/20/2024 | CalciMedica | CALC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/17/2024 | Capricor Therapeutics | CAPR | New Coverage | Outperform (N/A) |
5.33 (6.57) |
23.26% | Details | |
| 3/24/2023 | CalciMedica | CALC | New Coverage | Outperform (N/A) |
5.66 (2.21) |
-60.95% | Details | |
| 11/21/2022 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2022 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2022 | Trevi Therapeutics | TRVI | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/6/2022 | NuCana | NCNA | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/25/2022 | Trevi Therapeutics | TRVI | New Coverage | Outperform (N/A) |
2.25 (15.93) |
608% | Details | |
| 3/14/2022 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2022 | NuCana | NCNA | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/5/2021 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/30/2020 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/21/2020 | NuCana | NCNA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2020 | NuCana | NCNA | New Coverage | Outperform (N/A) |
5.22 (1.37) |
-73.75% | Details |
